

# Immuno-Oncology: A Renaissance in the Treatment of NSCLC

Sunday, 9 October 2016  
13:00 – 14:30

Industry Satellite  
Symposium  
Sponsored by MSD

Bella Center Copenhagen  
Athens Auditorium  
Copenhagen, Denmark

Chair: Frances Shepherd (Canada)

## CHAIR

### Frances Shepherd

Professor of Medicine  
University of Toronto  
Scott Taylor Chair in Lung Cancer  
Research  
Princess Margaret Hospital  
Toronto, Canada

## FACULTY

### Andrea Ardizzoni

Head, Medical Oncology  
S. Orsola-Malpighi University  
Hospital  
Bologna, Italy

### Reinhard Büttner

Professor and Chairman  
Institute for Pathology  
University Hospital  
Cologne, Germany

### Naiyer Rizvi

Professor of Medicine  
Director, Thoracic Oncology and Phase I  
Immunotherapeutics  
Price Chair in Clinical Translational  
Research  
Columbia University Medical Center  
New York, New York, USA

## Educational Objectives

- Establish a rationale for checkpoint inhibitors as a treatment option for lung cancer based on the mechanism of disease
- Educate on the immune-related adverse events associated with treatment of immunotherapies in lung cancer
- Educate on the role tumor expression can play in determining appropriate treatment options

## AGENDA

|               |  |                  |
|---------------|--|------------------|
| 13:00 – 13:05 | Welcome and Introduction               | Frances Shepherd |
| 13:05 – 13:20 | Anti-PD-1 Experience in NSCLC          | Frances Shepherd |
| 13:20 – 13:30 | The Value of PD-L1 Expression in NSCLC | Reinhard Büttner |
| 13:30 – 13:45 | Patient Management<br>• Example Case   | Naiyer Rizvi     |
| 13:45 – 14:00 | NSCLC Landscape: Future Directions     | Andrea Ardizzoni |
| 14:00 – 14:30 | Panel Discussion                       | Faculty          |
| 14:30         | Closing Remarks                        | Frances Shepherd |

*Presentations and patient cases were independently prepared by the speakers with no influence of MSD.*